RecruitingNCT05450978

Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding

Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding


Sponsor

University of Pittsburgh

Enrollment

60 participants

Start Date

Jul 20, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This project focuses on anti-seizure medication (ASM) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

  • Woman with epilepsy between the ages of 18-45 planning pregnancy or in the early first trimester of pregnancy.
  • Women with epilepsy ability to maintain a daily medical diary
  • Women with epilepsy ability to answer side effect questionnaires
  • Women with epilepsy currently being treated with lamotrigine (LTG) or levetiracetam (LEV) or oxcarbazepine (OXC)

Exclusion Criteria4

  • Women with epilepsy having history of functional seizures.
  • Women with epilepsy history of other major medical illnesses including renal or hepatic disease, progressive cerebral disease,
  • Women with epilepsy who have inability to maintain a seizure and medication daily diary
  • Women with epilepsy with present or recent history of drug or alcohol abuse, or the use of any concomitant medications that interact with the ASM they are taking (lamotrigine, levetiracetam, oxcarbazepine).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLamotrigine

Anti-seizure concentrations

DRUGLevetiracetam

Anti-seizure concentrations

DRUGOxcarbazepine

Anti-seizure concentrations


Locations(1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05450978


Related Trials